Horizon Pharma (HZNP) Could Buy Back All Shares Over 5 Years, Squeeze Shorts - Guggenheim
Get Alerts HZNP Hot Sheet
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 14
Join SI Premium – FREE
Guggenheim analyst, Louise Chen believes that Horizon Pharma (NASDAQ: HZNP) shares are range bound as the Street works through some overhangs (primary care business, generic competition for Vimovo, headline risks in healthcare). But the stock could be $40+ by year-end if the company successfully executes on its business objectives and the data for Actimmune FA is positive (4Q16). No change to Buy rating or $40 PT.
The analyst said solid execution and good data could squeeze the bears out of short positions.
There are 3 reasons for the analyst's thesis:
1) a sum-of-the-parts analysis arrives at a value of ~$50 per share — even if the Primary Care franchise is worth 0, the stock should still have 69% upside
2) one turn in P/E could drive shares up 16%
3) HZNP could buy back its entire market cap in 4-5 years
HZNP currently trades at 8x ’16E consensus EPS of $2.44. If the P/E multiple expands to 9x, the stock could be worth $22 per share and this equates to 16% upside potential. This could happen if HZNP’s execution were to just meet its stated objectives since Street expectations are modest to negative.
Potential Catalysts:
1) Pipeline advancements for Actimmune (FA, PD-1/PDL1 combo, less severe SMO)
2) M&A, '16+
3) Share gains for Duexis, Vimovo, Pennsaid, Actimmune, Ravicti, '16+
For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.
Shares of Horizon Pharma closed at $18.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Craig-Hallum Assumes Guardant Health (GH) at Buy, 'We think that GH is undervalued'
- Peoples Bancorp (PEBO) PT Lowered to $33 at Keefe, Bruyette & Woods
- Hong Kong Exchange (388:HK) (HKXCY) PT Lowered to HK$270 at HSBC
Create E-mail Alert Related Categories
Analyst Comments, Short SalesRelated Entities
Louise ChenSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!